Literature DB >> 20236349

Medication overuse headache: withdrawal and prophylactic therapeutic regimen.

Marco Trucco1, Piero Meineri, Luigi Ruiz, Maurizio Gionco.   

Abstract

BACKGROUND: Medication overuse headache (MOH) is a secondary headache, whose diagnostic criteria were settled by the Second Edition of the International Classification of Headache Disorders and its subsequent revisions. Its diagnosis and treatment represent a growing problem worldwide and a challenge for headache specialists.
OBJECTIVE: The aim of this study was to evaluate the efficacy of a therapeutic regimen for withdrawal of the overused drug and prophylaxis of headache in a population of patients suffering from MOH in 8 hospitals of Piemonte - Liguria - Valle d'Aosta. PATIENTS AND METHODS: Seventy patients, 58 females (82.9%) and 12 males (17.1%), mean age at observation 51.04 +/- 12.59 years, affected by MOH following International Headache Society diagnostic revised criteria were treated as inpatients (n = 40) or in Day Hospital (n = 30). Headache Index (HI) and Daily Drug Intake (DDI) were used for evaluating the severity of headache and medication overuse. The patients were treated by abrupt discontinuation of the overused drug and by a therapeutic protocol including i.v. hydration, dexhamethasone, metoclopramide, and benzodiazepines for 7-15 days. Prophylactic medication was started at the beginning of therapeutic protocol. Patients underwent follow-up controls 1, 3, and 6 months after discharge. The initial diagnosis was MOH in all patients included in the study. The overused medications were simple analgesics in 18 cases (25.7%), combination analgesics in 26 cases (37.1%), triptans alone in 9 cases (12.9%), or in combination with analgesics in 13 cases (18.6%), and ergot derivatives (in combination) in 4 cases (5.7%). We collected data from 59 patients at first follow-up (1 month), 56 after 3 months, and 42 after 6 months.
RESULTS: Mean HI was 0.92 at admission, 0.19 at discharge, 0.35 after 30 days, 0.39 after 3 months, and 0.42 after 6 months. Mean DDI was 2.72 at admission, 0.22 at discharge, 0.31 after 1 month, 0.38 after 3 months, and 0.47 after 6 months. These results proved to be highly statistically significant.
CONCLUSIONS: The protocol was generally effective, safe, and well-tolerated. The results tend to remain stable with time, and seem to be encouraging about long-term use of this therapeutic protocol on a larger number of patients suffering from MOH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20236349     DOI: 10.1111/j.1526-4610.2010.01631.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  10 in total

Review 1.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

2.  An emerging problem in clinical practice: how to treat chronic headache patients.

Authors:  Luigi Alberto Pini
Journal:  Intern Emerg Med       Date:  2010-12-07       Impact factor: 3.397

Review 3.  A Critical Evaluation on MOH Current Treatments.

Authors:  Andrea Negro; Martina Curto; Luana Lionetto; Simona Guerzoni; Luigi Alberto Pini; Paolo Martelletti
Journal:  Curr Treat Options Neurol       Date:  2017-08-15       Impact factor: 3.598

4.  The Efficacy of Japanese Herbal Kampo Medicine as an Acute and Prophylactic Medication to Treat Chronic Daily Headache and Medication Overuse Headache:-Single Arm Retrospective Study.

Authors:  Masahito Katsuki; Kenta Kashiwagi; Shin Kawamura; Akihito Koh
Journal:  Cureus       Date:  2022-05-27

Review 5.  Update of Inpatient Treatment for Refractory Chronic Daily Headache.

Authors:  Tzu-Hsien Lai; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2016-01

6.  Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India.

Authors:  Sanjay Prakash; Samir Saini; Kaushikkumar Ramanlal Rana; Pinaki Mahato
Journal:  J Headache Pain       Date:  2012-05-27       Impact factor: 7.277

Review 7.  Risk of medication overuse headache across classes of treatments for acute migraine.

Authors:  Kristian Thorlund; Christina Sun-Edelstein; Eric Druyts; Steve Kanters; Shanil Ebrahim; Rahul Bhambri; Elodie Ramos; Edward J Mills; Michel Lanteri-Minet; Stewart Tepper
Journal:  J Headache Pain       Date:  2016-11-24       Impact factor: 7.277

8.  Effect of selective serotonin reuptake inhibitor treatment on the prognosis of patients with medication overuse headache.

Authors:  Jinghuan Fang; Yang Zhang; Ning Chen; Jian Guo; Muke Zhou; Li He
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

9.  The impact of COVID-19 pandemic on headache symptoms and drug withdrawal among patients with medication overuse headache: a cross-sectional study.

Authors:  Changling Li; Yanbo Li; Mengmeng Ma; Yang Zhang; Jiajia Bao; Wenjing Ge; Yanqin Liu; Cheng Peng; Li He
Journal:  J Headache Pain       Date:  2021-05-21       Impact factor: 7.277

10.  Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.

Authors:  Michael J Marmura; Hans-Christoph Diener; Robert P Cowan; Stewart J Tepper; Merle L Diamond; Amaal J Starling; Joe Hirman; Lahar Mehta; Thomas Brevig; Roger Cady
Journal:  Headache       Date:  2021-09-22       Impact factor: 5.311

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.